Anle138b is an aggregation inhibitor that modulates the formation of pathological oligomers of both prion and α-synuclein.1 In mouse models of prion diseases and Parkinson’s disease, Anle138b strongly inhibited oligomer formation, neuronal degeneration, and disease progression even after disease onset.1,2 Anle138b has delayed disease progression and prevented motor decline in multiple neurodegenerative models.3-6 Treatment of melanoma cells with anle138b caused massive cell death via major dysregulation of autophagy revealing a protective effect of α-synuclein on autophagy in these cells.7 Orally bioavailable and able to cross the blood-brain barrier.
1) Wagner et al. (2013), Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease; Acta Neuropathol., 125 795
2) Levin et al. (2014), The oligomer modulator anle138b inhibits disease progression in a Parkinson’s mouse model even with treatment started after disease onset; Acta Neuropathol., 127 779
3) Wagner et al. (2015), Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies; Acta Neuropathol., 130 619
4) Martinez Hernandez et al. (2018), The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology; EMBO Mol. Med., 10 32
5) Heras-Garvin et al. (2019), Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy; Mov. Disord., 34 255
6) Brendel et al. (2019), Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimers disease tau; Alzheimer’s Res. Ther., 11 67
7) Turriani et al. (2017), Treatment with diphenyl-pyrazole compound anle138b reveals that α-synuclein protects melanoma cells from autophagic cell death; Proc. Natl. Acad. Sci. USA, 114 E4971